Takeda and Innovent fulfil close conditions for ADC and IO therapies
Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment of all closing conditions. In October 2025, the two companies signed the deal as part of …